Insulin resistance market tipped for steady expansion to 2036

The insulin resistance treatment market is set for sustained growth over the next decade, underpinned by rising obesity levels, expanding type 2 diabetes prevalence, and broader recognition of insulin resistance as a central driver of cardiometabolic disease, according to a new analysis from DelveInsight.

The USA is expected to remain the largest market, ahead of Europe’s four biggest economies, the UK, and Japan. Global prevalence was estimated at just over 26% in 2025, highlighting both the scale of the public health burden and the commercial potential for new therapies.

While lifestyle modification remains first-line management across major guidelines, drug treatment is increasingly shaped by therapies originally developed for diabetes and obesity. These include GLP-1-based medicines such as Ozempic (semaglutide) and Mounjaro (tirzepatide), which have helped expand payer and clinician focus on insulin sensitivity.